CAPTRUST Financial Advisors
RUBY

CAPTRUST Financial Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-150
Closed -$1K – 5251
2022
Q1 		$1K Buy
+150
New +$953 ﹤0.01% 4805
2021
Q3 		– Sell
-10
Closed – – 4837
2021
Q2 		$0 Hold
10
– – ﹤0.01% 4730
2021
Q1 		$0 Buy
+10
New +$146 ﹤0.01% 4531

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAPTRUST Financial Advisors's RUBY Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 150 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in RUBY in Q1 2021 and held it in 3 quarters. The position peaked at $1K in Q1 2022. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 150 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Rubius Therapeutics, Inc in Q1 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Rubius Therapeutics, Inc position peaked at $1K in Q1 2022.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.